Background: Dialysis with complement-activating membranes is associated with leukopenia, which is related to an increased expression of adhesion molecules on leukocytes. Citrate chelates calcium and has been claimed to attenuate leukopenia. Methods: In this study, the effects of citrate anticoagulation on leukocyte and granulocyte counts, complement activation, and the expression of CD11b, CD11c, and CD45 on the surface of granulocytes were evaluated during hemodialysis with unmodified cellulose membranes. Standard heparin was compared to citrate in three different schedules: citrate was infused to obtain a concentration of either 7 or 10 mmol/l blood. CaCl2 was administered into the dialyzer outlet at 8.25 mmol Ca2+/h (citrate 10 mmol/l) or at 11 mmol Ca2+/h (citrate 7 and 10 mmol/l) to restitute the calcium levels in the blood returning to the patient. Results: The use of citrate at a high concentration (10 mmol/l) was associated with a blunted upregulation of CD11b, both at the inlet and at the outlet bloodline; for CD11c a reduced upregulation was observed on granulocytes harvested from the inlet bloodline. No effects of citrate were observed on leukopenia, granulocytopenia, or complement activation. A positive correlation between the decrease in systemic ionized Ca2+ concentration and the increase in CD11b and CD11c expression was found. Conclusion: Citrate/CaCl2 administration affects leukocyte adhesion molecule expression in a dose-dependent way; however, no significant effect could be demonstrated on leukopenia and complement activation.

Keywords:
Adhesion molecule, Bioincompatibility, CD11b, CD11c, CD45, Citrate, Complement, Hemodialysis, Leukocytes
1.
Pinnick R, Wiegmann T, Diederich D: Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983;308:258–261.
2.
Wiegmann T, MacDougall M, Diederich D: Dialysis leukopenia, hypoxemia and anaphylatoxin formation: Effect of membrane, bath, and citrate anticoagulation. Am J Kidney Dis 1988;11:418–424.
3.
Böhler J, Schollmeyer P, Dressel B, Dobos G, Hörl W: Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: Dissociation of complement activation and neutropenia from neutrophil degranulation. J Am Soc Nephrol 1996;7:234– 241.
4.
Bos JC, Grooteman MP, van Houte AJ, Schoorl M, van Limbeek J, Nube MJ: Low polymorphonuclear cell degranulation during citrate anticoagulation: A comparison between citrate and heparin dialysis. Nephrol Dial Transplant 1997;12:1387–1393.
5.
Seaton R, Duncan K, Pinnick R, Diederich D, Wiegmann T: Regional citrate anticoagulation in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 1983;29:414–418.
6.
Janssen M, Huijgens P, Bouman A, Oe P, Donker A, Van Der Meulen J: Citrate versus heparin anticoagulation in chronic haemodialysis patients. Nephrol Dial Transplant 1993;8:1228–1233.
7.
Janssen M, Deegens J, Kapinga T, Beukhof J, Huijgens P, Van Loenen A, Van Der Meulen J: Citrate compared to low molecular weight heparin anticoagulation in chronic hemodialysis patients. Kidney Int 1996;49:806–813.
8.
Dhondt A, Vanholder R, Waterloos M, Glorieux G, De Smet R, Lameire N: Citrate anticoagulation does not correct cuprophane bioincompatibility as evaluated by the expression of leukocyte surface molecules. Nephrol Dial Transplant 1998;13:1752–1758.
9.
Craddock P, Fehr J, Dalmasso A, Brigham K, Jacob H: Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 1977;59:879–888.
10.
Arnaout M, Hakim R, Todd R, Dana N, Colten H: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 1985;312:457–462.
11.
Himmelfarb J, Zaoui P, Hakim R: Modulation of granulocyte LAM-1 and MAC-1 during dialysis – a prospective, randomized controlled trial. Kidney Int 1992;41:388–395.
12.
Alvarez V, Pulido R, Campanero M, Paraiso V, De Landazuri M, Sanchez-Madrid F: Differentially regulated cell surface expression of leukocyte adhesion receptors on neutrophils. Kidney Int 1991;40:899–905.
13.
Tielemans C, Delville J, Husson C, Madhoun P, Lambrechts A, Goldman M, Vanherweghem J: Adhesion molecules and leukocyte common antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993;39:158–165.
14.
Von Appen K, Goolsby C, Mehls P, Goewert R, Ivanovich P: Leukocyte adhesion molecules as biocompatibility markers for hemodialysis membranes. ASAIO J 1994;40:M609–M615.
15.
Dhondt A, Vanholder R, Waterloos M, Glorieux G, Ringoir S: Leukocyte CD14 and CD45 expression during hemodialysis: Polysulfone versus cuprophane. Nephron 1996;74:342– 348.
16.
Pulido R, Alvarez V, Mollinedo F, Sanchez-Madrid F: Biochemical and functional characterization of the leukocyte tyrosine phosphatase CD45 (CD45RO, 180 kD) from human neutrophils. In vivo upregulation of CD45RO plasma membrane expression in patients undergoing haemodialysis. Clin Exp Immunol 1992;87:329–335.
17.
Petruzelli L, Luk J, Springer T: Adhesion structure subpanel 5, leucocyte integrins: CD11a, CD11b, CD11c, and CD18; in Schlossman S, Boumsell L, Gilks W, Harlan J, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder T, Todd R (eds): Leukocyte Typing, vol 2. Oxford, Oxford University Press, 1995, pp 1588–1592.
18.
Donovan J, Koretzky G: CD45 and the immune response. J Am Soc Nephrol 1993;4:976–985.
19.
Smeby L, Wideroe T, Balstad T, Jorstad S: Biocompatibility aspects of cellophane, cellulose acetate, polyacrylonitrile, polysulfone and polycarbonate hemodialyzers. Blood Purif 1986;4:93–101.
20.
Chenoweth D, Henderson L: Complement activation during hemodialysis: Laboratory evaluation of hemodialyzers. Artif Organs 1987;11:155–162.
21.
Skroeder N, Kjellstrand P, Holmquist B, Kjellstrand C, Jacobson S: Individual differences in biocompatibility responses to hemodialsis. Int J Artif Organs 1994;17:521–530.
22.
Mahiout A, Heinhold H, Kessel M, Schulze H, Baurmeister U: Dialyzer membranes: Effect of surface area and chemical modification of cellulose on complement and platelet activation. Artif Organs 1987;11:149–154.
23.
Jagels M, Chambers J, Arfors K, Hugli T: C5a- and tumor necrosis factor-α-induced leukocytosis occurs independently of β2 integrins and L-selectin: Differental effects on neutrophil adhesion molecule expression in vivo. Blood 1995;85:2900–2909.
24.
Werfel T, Oppermann M, Schulze M, Krieger G, Weber M, Götze O: Binding of fluorescein-labeled anaphylatoxin C5a to human peripheral blood, spleen, and bone marrow leukocytes. Blood 1992;79:152–160.
25.
Berger M, O’Shea J, Cross A, Folks T, Chused T, Brown E, Frank M: Human neutrophils increase expression of C3bi as well as C3b receptors upon activation. J Clin Invest 1984;74:1566–1571.
26.
Todd R, Arnaout A, Rosin R, Crowley C, Peters W, Babior B: Subcellular localization of the large subunit of Mo1, a surface glycoprotein associated with neutrophil adhesion. J Clin Invest 1984;74:1280–1290.
27.
Kuijpers T, Hoogerwerf M, Roos D: Neutrophil migration across monolayers of resting or cytokine-activated endothelial cells. J Immunol 1992;148:72–77.
28.
Skroeder N, Kjellstrand P, Holmquist B, Nilsson U, Jacobson S. Increased amounts of C3a and the terminal complement complex at high dialysis blood-flow: The relation with dialysis efficiency. Nephron 1996;72:523–529.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.